ARTICLE | Company News

Diamyd endocrine, neurology news

November 1, 2010 7:00 AM UTC

The diabetes business will consist of its Diamyd diabetes vaccine, a recombinant human glutamic acid decarboxylase (GAD) 65 subcutaneous vaccine in Phase III testing to treat Type I diabetes. The pain business consists of compounds that use the company's Nerve Targeting Drug Delivery System (NTDDS) technology to deliver drugs directly to the nervous system to treat pain. The lead compound in the pain program is NP2 Enkephalin, a herpes simplex virus (HSV) vector delivering the enkephalin gene via the NTDDS in Phase I testing to treat chronic pain. ...